The science of amber.
AmberVax converts liquid biological drug substance into a stable, amorphous solid — a vitrified amber matrix that locks proteins, lipids and nucleic acids in their native conformation.
A glass — not a crystal — at the molecular scale.
Conventional freeze-drying creates micro-crystals that damage delicate biologics. AmberVax bypasses crystallization entirely. Our proprietary excipient systems and controlled dehydration form an amorphous glass that suspends the active molecule in molecular stasis.
The result: thermodynamic stability indistinguishable from a solid state, while preserving full biological activity on reconstitution.
Built on two decades of stabilization research.
Excipient chemistry and formulation IP that defines the vitrification matrix. Sugar-based glass formers, stabilizing surfactants and proprietary additives validated across modalities.
Process engineering and dehydration kinetics developed across more than 20 years of preclinical and clinical-grade stabilization programs in vaccines and biologics.
Stability data that redefines logistics.
Demonstrated ambient storage
Accelerated stability validated
Projected shelf life
Reconstitution time
Drop-in compatibility with existing fill-finish lines.
No new capital equipment. AmberVax formulations run on conventional lyophilization and aseptic processing infrastructure, with adapted cycle parameters for the vitrification stage.